Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lung Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Fallopian Tube Neoplasms 7Ovarian Neoplasms 6Colorectal Neoplasms 5Urinary Bladder Neoplasms 4Pancreatic Neoplasms 4Melanoma 4Carcinoma, Hepatocellular 4Glioblastoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Brain Neoplasms 3Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoid Interstitial Pneumonia 2Liposarcoma 2Carcinoma, Neuroendocrine 2Carcinoma 2Brenner Tumor 2Breast Neoplasms 2Adenocarcinoma, Mucinous 2

Interventions

pembrolizumab 3romidepsin 2Specimen Handling 2Melphalan 2Gemcitabine 2Etoposide 2Cyclophosphamide 2Biopsy 210-propargyl-10-deazaaminopterin 2tazemetostat 1talimogene laherparepvec 1prednylidene 1fludarabine 1etoposide phosphate 1durvalumab 1deltacortene 1cc-486 1carmustine, poliferprosan 20 drug combination 1belinostat 1Whole-Body Irradiation 1Triamcinolone 1Tacrolimus 1Prednisone 1Pharmacokinetics 1Pharmacogenomic Variants 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Nivolumab 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, T-Cell × Immunoglobulin G × Clear all
NCT03011814 2025-09-18

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Active not recruiting
38 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡